178 related articles for article (PubMed ID: 31703344)
21. Response to therapy of papillary thyroid cancer of known BRAF status.
Kowalska A; Walczyk A; Kowalik A; Pałyga I; Gąsior-Perczak D; Trybek T; Kopczyński J; Kajor M; Mikina E; Szymonek M; Gadawska-Juszczyk K; Szyska-Skrobot D; Lizis-Kolus K; Hurej S; Chrapek M; Chłopek M; Góźdź S
Clin Endocrinol (Oxf); 2017 Dec; 87(6):815-824. PubMed ID: 28718951
[TBL] [Abstract][Full Text] [Related]
22. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
Elisei R; Ugolini C; Viola D; Lupi C; Biagini A; Giannini R; Romei C; Miccoli P; Pinchera A; Basolo F
J Clin Endocrinol Metab; 2008 Oct; 93(10):3943-9. PubMed ID: 18682506
[TBL] [Abstract][Full Text] [Related]
23. Association Between BRAF
Shangguan R; Hu YP; Huang J; Yang SJ; Ye L; Lin RX; Zhu J; Zhang TL; Ying L; Li P
Acad Radiol; 2019 Feb; 26(2):154-160. PubMed ID: 29941398
[TBL] [Abstract][Full Text] [Related]
24. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
[TBL] [Abstract][Full Text] [Related]
25. Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma.
Yan C; Huang M; Li X; Wang T; Ling R
Endocr Connect; 2019 Jul; 8(7):988-996. PubMed ID: 31252408
[TBL] [Abstract][Full Text] [Related]
26. Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma.
Park AY; Son EJ; Kim JA; Youk JH; Park YJ; Park CS; Chang HS
PLoS One; 2014; 9(10):e110868. PubMed ID: 25337709
[TBL] [Abstract][Full Text] [Related]
27. The Coexistence of Genetic Mutations in Thyroid Carcinoma Predicts Histopathological Factors Associated With a Poor Prognosis: A Systematic Review and Network Meta-Analysis.
Zhao L; Wang L; Jia X; Hu X; Pang P; Zhao S; Wang Y; Wang J; Zhang Y; Lyu Z
Front Oncol; 2020; 10():540238. PubMed ID: 33240806
[TBL] [Abstract][Full Text] [Related]
28. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
Guerra A; Zeppa P; Bifulco M; Vitale M
Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056
[TBL] [Abstract][Full Text] [Related]
29. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.
Lupi C; Giannini R; Ugolini C; Proietti A; Berti P; Minuto M; Materazzi G; Elisei R; Santoro M; Miccoli P; Basolo F
J Clin Endocrinol Metab; 2007 Nov; 92(11):4085-90. PubMed ID: 17785355
[TBL] [Abstract][Full Text] [Related]
30. Association between BRAF
Lu HZ; Qiu T; Ying JM; Lyn N
Oncol Lett; 2017 Mar; 13(3):1595-1600. PubMed ID: 28454296
[TBL] [Abstract][Full Text] [Related]
31. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.
Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ
Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825
[TBL] [Abstract][Full Text] [Related]
32. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
[TBL] [Abstract][Full Text] [Related]
33. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.
Kim TH; Park YJ; Lim JA; Ahn HY; Lee EK; Lee YJ; Kim KW; Hahn SK; Youn YK; Kim KH; Cho BY; Park DJ
Cancer; 2012 Apr; 118(7):1764-73. PubMed ID: 21882184
[TBL] [Abstract][Full Text] [Related]
34. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
[TBL] [Abstract][Full Text] [Related]
35. Pathologic Characteristics, Natural History, and Prognostic Implications of BRAF
Hardee S; Prasad ML; Hui P; Dinauer CA; Morotti RA
Pediatr Dev Pathol; 2017 Jun; 20(3):206-212. PubMed ID: 28521635
[TBL] [Abstract][Full Text] [Related]
36. Imbalance in DNA repair machinery is associated with BRAF
Lutz BS; Leguisamo NM; Cabral NK; Gloria HC; Reiter KC; Agnes G; Zanella V; Meyer ELS; Saffi J
Mol Cell Endocrinol; 2018 Sep; 472():140-148. PubMed ID: 29229408
[TBL] [Abstract][Full Text] [Related]
37. Mutations of the
Liu R; Li Y; Chen W; Cong J; Zhang Z; Ma L; Chu L; Xiao H; Zhang Y; Liu Y; Xu Y; Yu Q; Yang X; Sun C
Oncol Lett; 2020 Oct; 20(4):50. PubMed ID: 32802170
[TBL] [Abstract][Full Text] [Related]
38. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.
Elisei R; Viola D; Torregrossa L; Giannini R; Romei C; Ugolini C; Molinaro E; Agate L; Biagini A; Lupi C; Valerio L; Materazzi G; Miccoli P; Piaggi P; Pinchera A; Vitti P; Basolo F
J Clin Endocrinol Metab; 2012 Dec; 97(12):4390-8. PubMed ID: 23066120
[TBL] [Abstract][Full Text] [Related]
39. Meta-Analyses of Association Between BRAF(V600E) Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma.
Zhang Q; Liu SZ; Zhang Q; Guan YX; Chen QJ; Zhu QY
Cell Physiol Biochem; 2016; 38(2):763-76. PubMed ID: 26871894
[TBL] [Abstract][Full Text] [Related]
40. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]